🇺🇸 FDA
Pipeline program

VP-102

VP-CW-301

Phase 3 other active

Quick answer

VP-102 for Common Warts is a Phase 3 program (other) at Verrica Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Verrica Pharmaceuticals
Indication
Common Warts
Phase
Phase 3
Modality
other
Status
active

Clinical trials